Programmable small extracellular vesicles for delivery of therapeutic molecules

Modified sEVs with tissue homing peptides address the limitations of current nanoparticles by achieving targeted and efficient delivery of therapeutic molecules to specific organs and tissues, including the brain, with high specificity and bioavailability.

WO2026241732A1PCT designated stage Publication Date: 2026-11-19NUTECH VENTURES LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028524
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current nanoparticles for therapeutic delivery are rapidly eliminated by macrophages, do not accumulate specifically in target tissues, are degraded in lysosomes, and may not be orally bioavailable or cross the blood-brain barrier effectively.

Method used

Modified small extracellular vesicles (sEVs), such as programmable milk exosomes (PMEs), are engineered with tissue homing peptides that covalently bind to the sEV surface, enabling targeted delivery to specific organs and tissues, including the brain, and are orally bioavailable and efficient at crossing the blood-brain barrier.

Benefits of technology

The modified sEVs achieve specific accumulation in target tissues and organs, protect therapeutic cargo from degradation, and provide efficient delivery of therapeutic molecules like gene editors, with minimal off-target effects and immunogenicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000032_0001_TABLE
    Figure IMGF000032_0001_TABLE
  • Figure IMGF000032_0002_TABLE
    Figure IMGF000032_0002_TABLE
  • Figure IMGF000035_0001_TABLE
    Figure IMGF000035_0001_TABLE
Patent Text Reader

Abstract

Small extracellular vesicles (sEVs) linked to a peptide that steers the sEV to a target tissue are provided herein. The associated compositions, and use the sEVs and sEV compositions to deliver therapeutic molecules of interest, such as genes and gene editors, to the target tissue or organ, or treating a disease are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

2025-132-02PROGRAMMABLE SMALL EXTRACELLULAR VESICLES FOR DELIVERY OF THERAPEUTIC MOLECULESInventor: Janos ZempleniCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present patent application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 806,377. filed May 15, 2025, the entire contents of which are incorporated by reference herein.SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been filed electronically in extensible Markup Language (XML) format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 15, 2026, is named N109577_2040_SL.xml and is 8,886 bytes in size.STATEMENT OF GOVERNMENT SUPPORT

[0003] This invention was made with government support under Grant Nos. P20 GM 104320 and P30 GM154608 awarded by the National Institutes of Health. The government has certain rights in the invention.TECHNICAL FIELD

[0004] The disclosure relates to small extracellular vesicles and use thereof.BACKGROUND

[0005] Synthetic and cell culture-derived nanoparticles (small extracellular vesicles, sEVs, “exosomes”) have attracted considerable attention and yielded successes in the prevention, treatment, and cure of disease by delivering therapeutics to sites of disease. sEVs are secreted by virtually every living cell and are detectable in all body fluids studied to date. sEVs facilitate intercellular communication by transferring endogenous regulatory cargos (proteins, lipids, RNA) from donor cells to recipient cells. Milk sEVs ("MEs"). such as from bovine milk, ovine milk, or caprine milk, are a particular type of sEVs. However, the following challenges currently limit the use of nanoparticles in the delivery of therapeutics: 1) currently available nanoparticles (and therapeutic cargo) are rapidly eliminated by circulating and2025-132-02tissue macrophages; 2) currently available nanoparticles (and therapeutic cargo) do not accumulate specifically in a diseased tissue or cell type that is the target of treatment; 3) a large fraction of currently available nanoparticles (and therapeutic cargo) may be degraded in lysosomes upon internalization by target cells; and 4) currently available nanoparticles may not be orally bioavailable or efficiently cross the blood brain barrier.SUMMARY

[0006] Provided herein are modified small extracellular vesicles (sEVs) exosomes to deliver therapeutic molecules, such as genes and gene editors, to a target tissue or organ. These modified sEVs, such as programmable milk exosomes (PMEs), also referred to as designer milk exosomes (DMEs), can deliver and accumulate therapeutic molecules (such as gene editors) to target organs, tissues, and cells, such as the brain, hippocampus, neurons, heart, pancreas, lung, liver, and tumors. Unlike other nanocarriers, the sEVs of the present disclosure including DMEs are orally bioavailable and can cross the blood-brain barrier with great efficiency.

[0007] In one aspect, the present disclosure provides a small extracellular vesicle (sEV) containing a tissue homing peptide attached to the sEV.

[0008] In some embodiments, the sEV is derived from mammalian milk, or comprises a size, morphology, and bioavailability equivalent to an sEV derived from mammalian milk.

[0009] In some embodiments, the tissue homing peptide comprises a carbonyl-reactive peptide, and binds covalently to a carbonyl residue on the sEV surface. In some embodiments, the carbonyl residue is on a CD81 protein on the sEV surface. In some embodiments, the tissue homing peptide is a brain homing peptide, a hippocampus homing peptide, a neuron homing peptide, a heart homing peptide, a pancreas homing peptide, a lung homing peptide, a liver homing peptide, or a cancer homing peptide. In some embodiments, the tissue homing peptide is a brain homing peptide and is derived from a rabies virus glycoprotein (RVG). In some embodiments, the tissue homing peptide is a neuron homing peptide and comprises Tetl. In some embodiments, the tissue homing peptide comprises a rabies virus glycoprotein (RVG)-derived peptide and / or Tetl. In some embodiments, the tissue homing peptide is a hippocampus homing peptide and comprises the amino acid sequence of CDAGRKQKC (SEQ ID NO: 1). In some embodiments, the tissue homing peptide is a heart homing peptide and comprises the amino acid sequence of CRPPR (SEQ ID NO: 2). In some embodiments, the tissue homing peptide is a pancreas homing peptide and2025-132-02comprises the amino acid sequence of LSALPRT (SEQ ID NO: 3). In some embodiments, the tissue homing peptide is a lung homing peptide and comprises the amino acid sequence of CTSTRKKQC (SEQ ID NO: 4). In some embodiments, the tissue homing peptide is a liver homing peptide and comprises the amino acid sequence of RDEAKRF (SEQ ID NO: 5). In some embodiments, the tissue homing peptide is a cancer homing peptide. In some embodiments, the cancer homing peptide is a glioma homing peptide and comprises CooP or apoE.

[0010] In some embodiments, the tissue homing peptide comprises a tag, such as a histidine tag. In some embodiments, the tissue homing peptide further comprises one or more spacers. In some embodiments, the tissue homing peptide comprises the amino acid sequence of GSGHHHHHHGSG (SEQ ID NO: 6).

[0011] In some embodiments, the sEV comprises cargo. In some embodiments, the cargo comprises a gene editing agent, a protein, a plasmid, or a small interfering RNA. In some embodiments, the gene editing agent comprises a CRISPR-Cas9 enzyme and a guide RNA. In some embodiments, the plasmid encodes SYNGAP1 or MAGEL2.

[0012] In some embodiments, the sEV further contains a detectable label. In some embodiments, the detectable label includes a fluorophore, a chemiluminescent dye, a pH-sensitive dye, or a combination thereof.

[0013] In some embodiments, the sEV has a size of about 30 to about 150 nm.

[0014] In some embodiments, the sEV further comprises a CD47 peptide attached to the sEV.

[0015] In one aspect, provided herein is a pharmaceutical composition containing a therapeutically effective amount of the sEV provided herein. In some embodiments, the sEV is lyophilized and the pharmaceutical composition comprises about 3% trehalose.

[0016] In one aspect, provided herein is a method of delivering a therapeutic molecule to a target tissue or a target organ in a subject. The method includes administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a tissue homing peptide attached to the sEV and the therapeutic molecule.

[0017] In some embodiments, the sEV is derived from mammalian milk, or comprises a size, morphology, and bioavailability equivalent to an sEV derived from mammalian milk.

[0018] In some embodiments, the tissue homing peptide includes a carbonyl-reactive peptide, and binds covalently to a carbonyl residue on the sEV surface. In some2025-132-02embodiments, the tissue homing peptide is a brain homing peptide, a neuron homing peptide, a hippocampus homing peptide, a heart homing peptide, a pancreas homing peptide, a lung homing peptide, a liver homing peptide, or a cancer homing peptide. In some embodiments, the tissue homing peptide is a brain homing peptide and is derived from a rabies virus glycoprotein (RVG). In some embodiments, the tissue homing peptide is a neuron homing peptide and comprises Tetl. In some embodiments, the tissue homing peptide comprises a rabies virus glycoprotein (RVG)-derived peptide and / or Tetl. In some embodiments, the tissue homing peptide is a hippocampus homing peptide and comprises the amino acid sequence of CDAGRKQKC (SEQ ID NO: 1). In some embodiments, the tissue homing peptide is a heart homing peptide and comprises the amino acid sequence of CRPPR (SEQ ID NO: 2). In some embodiments, the tissue homing peptide is a pancreas homing peptide and comprises the amino acid sequence of LSALPRT (SEQ ID NO: 3). In some embodiments, the tissue homing peptide is a lung homing peptide and comprises the amino acid sequence of CTSTRKKQC (SEQ ID NO: 4). In some embodiments, the tissue homing peptide is a liver homing peptide and comprises the amino acid sequence of RDEAKRF (SEQ ID NO: 5). In some embodiments, the tissue homing peptide is a cancer homing peptide. In some embodiments, the cancer homing peptide is a glioma homing peptide and comprises CooP or apoE.

[0019] In some embodiments, the tissue homing peptide comprises a tag and / or one or more spacers. In some embodiments, the tissue homing peptide comprises the amino acid sequence of GSGHHHHHHGSG (SEQ ID NO: 6).

[0020] In some embodiments, the therapeutic molecule includes a gene editing agent, a protein, a plasmid, or a small interfering RNA. In some embodiments, the gene editing agent includes a CRISPR-Cas9 enzy me and a guide RNA. In some embodiments, the plasmid encodes SYNGAP1 orMAGEL2.

[0021] In some embodiments, the sEV further comprises a detectable label. In some embodiments, the detectable label comprises a fluorophore, a chemiluminescent dye, a pH-sensitive dye, or a combination thereof.

[0022] In some embodiments, the sEV further comprises a CD47 peptide attached to the sEV.

[0023] In one aspect, provided herein is a method of modifying a small extracellular vesicle (sEV). The method includes attaching a carbonyl-reactive peptide to a carbonyl residue on the sEV surface.2025-132-02

[0024] In some embodiments, the carbonyl-reactive peptide is a tissue homing peptide.

[0025] In some embodiments, the tissue homing peptide is a brain homing peptide, a neuron homing peptide, a hippocampus homing peptide, a heart homing peptide, a pancreas homing peptide, a lung homing peptide, a liver homing peptide, or a cancer homing peptide.

[0026] In some embodiments, the tissue homing peptide is a brain homing peptide and is derived from rabies virus glycoprotein (RVG). In some embodiments, the tissue homing peptide is a neuron homing peptide and comprises Tetl. In some embodiments, the tissue homing peptide comprises a rabies virus glycoprotein (RVG)-derived peptide and / or Tetl. In some embodiments, the tissue homing peptide is a hippocampus homing peptide and comprises the amino acid sequence of CDAGRKQKC (SEQ ID NO: 1). In some embodiments, the tissue homing peptide is a heart homing peptide and comprises the amino acid sequence of CRPPR (SEQ ID NO: 2). In some embodiments, the tissue homing peptide is a pancreas homing peptide and comprises the amino acid sequence of LSALPRT (SEQ ID NO: 3). In some embodiments, the tissue homing peptide is a lung homing peptide and comprises the amino acid sequence of CTSTRKKQC (SEQ ID NO: 4). In some embodiments, the tissue homing peptide is a liver homing peptide and comprises the amino acid sequence of RDEAKRF (SEQ ID NO: 5). In some embodiments, the tissue homing peptide is a cancer homing peptide. In some embodiments, the cancer homing peptide is a glioma homing peptide and comprises CooP or apoE.

[0027] In some embodiments, the tissue homing peptide comprises a tag and / or one or more spacers. In some embodiments, the tissue homing peptide comprises the amino acid sequence of GSGHHHHHHGSG (SEQ ID NO: 6).

[0028] In some embodiments, the method further includes loading cargo onto the sEV. In some embodiments, the cargo comprises a gene editing agent, a protein, a plasmid, or a small interfering RNA. In some embodiments, the gene editing agent comprises a CRISPR-Cas9 enzyme and a guide RNA. In some embodiments, the plasmid encodes SYNGAP1 or MAGEL2.

[0029] In some embodiments, the method further comprises lyophilizing the sEV with about 3% trehalose.

[0030] In some embodiments, the method further comprises capturing the sEV on a Ni2+-charged affinity resin, and purifying the sEVs.

[0031] In some embodiments, the method further comprises sterilizing the sEV by filtration through a membrane filter followed by high-pressure processing.2025-132-02

[0032] In one aspect, the present disclosure provides a method of treating a disease in a subject in need thereof. The method includes administering a therapeutically effective amount of a small extracellular vesicle (sEV) comprising a tissue homing peptide attached to the sEV and a therapeutic molecule, wherein the sEV delivers the therapeutic molecule to a target tissue or organ affected by the disease.

[0033] In some embodiments, the disease is glioblastoma multiforme, SYNGAP1 haploinsufficiency, a MAGEL2-associated disease, a heart disease, or a rare disease.BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0035] The accompanying drawings, which are included to provide a further understanding of the embodiments of the present disclosure, are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure, and together with the detailed description, serve to explain principles of the embodiments discussed herein. No attempt is made to show structural details of this disclosure in more detail than may be necessary for a fundamental understanding of the embodiments discussed herein and the numerous ways in which they may be practiced. According to customary practice, the various features of the drawings discussed below are not necessarily drawn to scale. Dimensions of various features and elements in the drawings may be expanded or reduced to illustrate embodiments of the disclosure more clearly.

[0036] FIGs. 1A and IB depict tissue homing of designer milk exosomes (DMEs) attached to a hippocampus homing peptide. FIG. 1A depicts accumulation in various murine tissues. FIG. IB depicts accumulation in distinct brain regions. L and R, left and right hemispheres. Three hours after tail vein injection (1011DMEs / g).

[0037] FIG. 2 depicts tissue homing of DMEs attached to a heart homing peptide (1011DMEs / g) administered via tail vein injection.

[0038] FIG. 3 depicts tissue homing of DMEs decorated with a pancreas homing peptide (1011DMEs / g).

[0039] FIGs.4A and 4B depict tissue homing of DMEs attached to a brain homing peptide (denved from Rabies Virus Glycoprotein, RVG). FIG. 4A depicts accumulation in various2025-132-02mouse tissues. FIG. 4B depicts accumulation in distinct brain regions. 1011DMEs / g were administered via tail vein injection.

[0040] FIG. 5 depicts In Vivo Imaging System (IVIS) images (enhanced green fluorescent protein (EGFP channel) of the tissues after single oral delivery of EGFP-MAGEL2 loaded milk exosomes (MEs) in mice. The mice were administered a single oral dose of 1.7 x IO10MEs per g body weight. Images were captured 72 hours after treatment.

[0041] FIG. 6 depicts IVIS images (EGFP channel) of the tissues after repeated oral delivery of EGFP-MAGEL2 loaded milk exosomes (MEs) in mice. The mice were administered repeated oral doses of 1.7 x 1010MEs per g body weight per dose on days 1, 3, and 5. Images were captured on day 7.

[0042] FIGs. 7A and 7B depict knocking out EGFP expression by delivery of gene editing agents by DMEs. FIG. 7A depicts EGFP expression in reporter cells before and 9 days after treatment with two EGFP gRNAs loaded on and delivered by Cas9-positive DMEs. FIG. 7B depicts EGFP fluorescence in target (top) and non-target (bottom) tissues in EGFP reporter mice after intravenous inj ection of Cas9-positive DMEs attached to a respective tissue homing peptide and loaded with EGFP gRNAs.

[0043] FIGs.8A-8C depict tissue homing of DMEs attached to a neuron homing peptide Tetl with or without a brain homing RVG peptide. FIG. 8A depicts individual organ images showing HiLyte Fluor™ 750-labeled bovine milk exosomes (BMEs) 3 hours post-tail vein administration. FIG. 8B depicts brain sections revealing a higher HiLyte1 1Fluor signal in the cerebrum and cerebellum for the Tetl+RVG peptide treated group than the Vehicle group administered HiLyte only. FIG. 8C depicts individual organ images revealing the Vehicle group with the highest HiLyte™ Fluor signal in all organs except the brain, while the Tetl+RVG group exhibited equal distribution across organs, with enhanced brain targeting.

[0044] FIG. 9 depicts tissue homing of DMEs decorated with a lung homing peptide or a hepatocyte homing peptide following a single oral dose in mice. Individual organ images show HiLyte ™ Fluor 750-labeled bovine milk exosomes (BMEs) 12 hours post-oral administration across six groups: PBS, lung peptide buffer (L-Buffer), hepatocyte peptide buffer (He-Buffer), BMEs, lung-targeting DMEs (L-DMEs), and hepatocyte-targeting DMEs (He-DMEs). Quantification of HiLyte™ Fluor 750 signal across tissues demonstrated selective accumulation of L-DMEs in the lung and He-DMEs in the liver.

[0045] FIG. 10 depicts localization of glioma homing peptide-decorated DMEs to tumors in a mouse xenograft model of human glioblastoma multiforme (GBM). DMEs decorated2025-132-02with CooP or ApoE glioma homing peptides were administered by tail vein injection at a dose of 0.25 x 1014DMEs / kg.

[0046] FIGs. 11A and 11B depict reduced macrophage elimination of DMEs decorated with a “Don't-eat-me” peptide, CD47. FIG. 11A depicts plasma levels of CD47-positive DMEs compared to CD47-negative DMEs two hours after tail vein injection in female mice.FIG. 11B depicts DME accumulation in the brain following nasal administration at a dose of 4.1 x 1010 DMEs / kg.

[0047] FIG. 12 depicts knockdown of IDH1 protein expression in malignant glioma U-87 cells following treatment with DMEs loaded with an IDH1 CRISPR / Cas9 plasmid encoding Cas9 and three gRNAs targeting the IDH1(R132H) mutant allele.

[0048] FIGs. 13A-13C depict restoration of SYNGAP1 protein expression in whole brains from Syngapl haploinsuffi cient mice treated with plasmid-loaded MEs. FIG. 13A depicts SYNGAP1 expression following treatment with 0.7 x 1014DMEs / kg every other day for 14 days by nasal spray. FIG. 13B depicts SYNGAP1 expression following treatment with 0.7 x 1014DMEs / kg every other day for 6 days. FIG. 13C depicts SYNGAP1 expression following a single low dose of 1.5 x 1011 DMEs / kg by nasal spray.

[0049] FIGs. 14A and 14B depict oral delivery of an EGFP-MAGEL2 plasmid by MEs in female C57BL / 6J mice. FIG. 14A depicts expression of the EGFP-MAGEL2 fusion protein in the brain following a single oral dose of l.7 x 1013 DMEs / kg. FIG. 14B depicts expression of the fusion protein following three oral doses administered on days 1, 3, and 5, with brains harvested on day 7.

[0050] FIGs. 15A and 15B depict cross-species delivery of DMEs in swine. DMEs decorated with a neuron homing peptide (Tetl) and an auxiliary peptide (RVG) and loaded with a plasmid encoding iRFP were administered orally to three-day-old male swine at a dose of 2.5 x 1011DMEs / kg. FIG. 15A depicts iRFP fluorescence in neuronal cells of the porcine brain. FIG. 15B depicts the absence of iRFP fluorescence in the spleen, demonstrating tissue specificity. C = cerebellum, LH = left hemisphere.

[0051] FIGs. 16A-16C depict intrauterine delivery of MEs and ME cargo across the placenta to murine embryos. FIG. 16A depicts accumulation of DiR-labeled MEs in the embryo and placenta compared to unlabeled ME controls on embryonic day 16.5. FIG. 16B depicts detection of IRDye-labeled miR-30d in the embryo and placenta following ME-mediated delivery'. FIG. 16C depicts detection of IRDye-labeled miR-21-5p in the embry o and placenta, confirming that MEs can deliver small RNA cargo across the placenta.2025-132-02

[0052] FIGs. 17A and 17B depict storage stability of milk exosomes (MEs) preserved by trehalose during lyophilization. FIG. 17A depicts ME counts following lyophilization in the presence of graded concentrations of trehalose. FIG. 17B depicts preservation of tissue distribution patterns of DMEs lyophilized in the presence of 3% trehalose, three hours after tail vein injection in male mice at a dose of 101?DMEs / kg.

[0053] FIGs. 18A and 18B depict the effects of membrane filtration and high-pressure processing (HPP) on DME (PME) count (FIG. 18A) and microbial growth (FIG. 18B), respectively; filtration plus HPP preserved count within experimental variability and eliminated detectable colony forming units under Gram-positive, Gram-negative, and fungal culture conditions.

[0054] FIGs. 19A and 19B depict homogeneity of DME preparations assessed during sequential purification. FIG. 19A depicts relative abundance of an exosome marker (CD9) and a whey protein contaminant (beta-lactoglobuhn) during purification by size exclusion chromatography (SEC), sucrose density gradient centrifugation (SDGC), and affinity purification. FIG. 19B depicts representative immunoblots confirming progressive enrichment of the exosome marker and removal of the contaminant.

[0055] FIG. 20 depicts transmission electron microscopy (TEM) revealing that DMEs were finely dispersed in phosphate-buffered saline with less than about ten percent of vesicles attached to other vesicles across three configurations.

[0056] FIGs. 21A-21C depict authentication of MEs isolated from bovine milk. FIG. 21A depicts size and count of MEs by nanoparticle tracking analysis (NT A). FIG. 21B depicts morphology and dispersion of MEs by transmission electron microscopy (TEM). FIG. 21C depicts immunoblots showing expression of positive exosome markers (CD63. heat shock protein 70 (HSP70), and ALG-2 interacting protein X (Alix)) and absence of negative markers (apolipoprotein B-100 (apoB), 0-integrin ([Tint.). histone H3 (H3), and butyrophilin (Butyr.)).

[0057] FIG. 22 depicts immunoblots showing enrichment of canonical exosome marker proteins (including CD9, CD81, and TsglOl) through sequential purification by ultracentrifugation (UC), size exclusion chromatography (SEC), sucrose density gradient centrifugation (SDGC).

[0058] FIG. 23 depicts immunoblots for proteins frequently encountered as contaminants in conventional milk exosome preparations, demonstrating their reduction2025-132-02to non-detectable levels under rigorous purification, including histone H3, integrin beta 1, beta-lactoglobulin, and apoB-100.

[0059] FIGs.24A and 24B depict affinity purification of DMEs using a poly -histidine (His6) tag. FIG. 24A depicts capture of His6-tagged DMEs on Ni2+resin and release by sequential imidazole washes. FIG. 24B depicts retained homing peptide functionality of DMEs decorated with a His6-tagged pancreas homing peptide, showing localization to the pancreas at a dose of 1011DMEs / kg in female mice.

[0060] FIG. 25 depicts peptide identity’ and purity analytics, including HPLC chromatograms and mass spectra, for synthetic homing peptides used to decorate DMEs, showing purity at or above about ninety-five percent with aqueous solubility under the stated modifications.

[0061] FIGs. 26A and 26B depict quantification of DNA associated with BMEs demonstrating that essentially all detectable DNA is adsorbed to the outer surface and eliminated by DNase treatment (FIG. 26A), including under carrier RNA supplementation conditions that enhance extraction sensitivity (FIG. 26B). ns = not significant, **** = p < 0.0001.DETAILED DESCRIPTION

[0062] The description may use the phrases ’‘in certain embodiments,’’ “in various embodiments,” “in an embodiment,” or “in embodiments,” which may each refer to one or more of the same or different embodiments. Furthermore, the terms “comprising,” “including,” “having,” and the like, as used with respect to embodiments of the present disclosure, are synonymous. The terms “about” and “approximately” are defined as being close to as understood by one of ordinary skill in the art. In one non-limiting embodiment, the terms are defined to be within 10%, preferably within 5%, more preferably within 1%, and most preferably within 0.5%. The term “removing,” “removed,” “reducing.” “reduced,” or any variation thereof, when used in the claims and / or the specification includes any measurable decrease of one or more components in a mixture to achieve a desired result. The use of the words “a” or “an” when used in conjunction with any of the terms “comprising,” “including,” “containing,” or “having,” in the claims or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The term “plurality” as used herein refers to two or more items or components. The term “wt.%,” “vol.%,” or “mol.%” refers to a weight, volume, or molar percentage of a2025-132-02component, respectively, based on the total weight, the total volume of material, or total moles, which includes the component. In a non-limiting example. 10 grams of component in 100 grams of the material is 10 wt.% of that component in the material.

[0063] As used herein, a “subject’" is an animal, such as a mammal, including a primate (such as a human, a non-human primate, such as a monkey) and a non-primate (such as a cow, a dog, a horse, a sheep, a rabbit, a cat, a rat, or a mouse). In some aspects of the invention, the subject is a human. The subject can be an adult subject or a pediatric subject, such as a neonate, an infant, or a child. The subject can be a patient. A “patient” as used herein refers to a human individual who has or is suspected of having a disease or condition, and / or who is a candidate for or benefits from a treatment for the disease or condition.A. Modified small extracellular vesicles

[0064] A modified small extracellular vesicle (sEV) is provided. The term “extracellular vesicle” (EV) describes membrane-bound, anucleate particles released by cells with a size range of about 10 nm to 10 pm in size. In some cases, the EV is about 20 nm to 10 pm, about 20 nm to 1 pm, about 20 nm-500 nm, about 30 nm-100 nm, about 30 nm-160 nm, or about 80-160 nm in size. In some embodiments, the EVs are exosomes that are about 20 to 150 nm in size. EVs can be broadly classified into three groups based on their size, molecular composition, and sub-cellular origins: small EVs (sEVs), medium EVs (mEVs), and large EVs (lEVs). Without wishing to be bound by theory , and by way of example but not limitation, sEVs can range about less than 200 nm in size, while medium EVs (mEVs) and large EVs (lEVs) can range about more than 200 nm and 1000 nm in size, respectively. In specific embodiments, sEVs are about 30-150 nm in size. In some cases, the EV is a cell-derived EV. “EV” also includes a lipid vesicle engineered to contain bioactive molecules found in a cell-derived EVs.

[0065] The term “small extracellular vesicle” (sEV) can include any type of membrane-delimited particle that has a diameter of about less than 200 nm, including exosomes and smaller microvesicles. Without wishing to be bound by theory’, sEVs transfer bioactive molecules between cells and are involved in cellular homeostasis and tumor development, where sEVs contributes to the formation of the premetastatic niche and to their altered metabolism.

[0066] The term “milk exosome” (ME) refers to an exosome derived (such as isolated or purified) from milk, such as mammalian milk. ME also refers to sEVs comprising a size,2025-132-02morphology, and bioavailability equivalent to an sEV derived from milk, such as mammalian milk. ME can be sEVs. For example, MEs can be derived from cells (such as a cell line), and can be of a size, morphology, and bioavailability equivalent to an sEV derived from milk (such as bovine milk, ovine milk, or caprine milk). MEs have qualities desired in nanomedicine, such as oral bioavailability, ability to cross barriers such as placenta and the blood-brain barrier, protection of payload in the gastrointestinal tract and industrial processing, and undetectable toxicity and immunogenicity.

[0067] Provided herein are synthetic carbonyl-reactive peptides for modifying sEVs such as exosomes, such as exosomes purified from milk (MEs). Also provided herein are sEVs (such as milk exosomes) modified by the carbonyl-reactive peptides, which can be referred to as “modified sEVs” or “programmable sEVs” or ““designer sEVs” or “modified milk exosomes” or “programmable milk exosomes (PMEs)” or “designer milk exosomes” (DMEs). The carbonyl-reactive peptides bind covalently to carbonyl residues on the surface of sEVs. Designer sEVs (including DMEs) offer at least the following advantages compared to currently existing delivery platforms:• The preparation of sEVs (such as DMEs) is technically straightforward and functional. sEVs (such as DMEs) can be produced from mammalian milk at scale. For example, a cow produces 10.800 kg milk annually and one milliliter of milk contains 1014sEVs, which equates to 1021sEVs per cow annually. Further, the production of sEVs (such as DMEs) can be done at a reasonable cost.• sEVs (such as DMEs) can be delivered non-invasively by mouth or intranasally (such as by nasal spray). Other routes of administration, such as intravenous administration, are also feasible and effective.• sEVs can be designed and modified to deliver cargo (such as gene editing agents) to any tissue of choice. Some sEVs, such as milk exosomes, can cross physiologic barriers such as intestinal mucosa, blood vessel endothelia, blood-brain barrier, and placenta for delivery to a target cell, tissue, or organ. Attaching a tissue homing peptide enhances the ability of sEVs (such as DMEs) to cross physiologic barriers such as intestinal mucosa, blood vessel endothelia, blood-brain barrier, and placenta for delivery at a target tissue or organ of interest, and decreases the accumulation of sEVs in non-target tissues.• sEVs (such as DMEs) are biologically safe and do not elicit an immunogenic reaction.2025-132-02

[0068] sEVs, such as MEs and DMEs, are versatile and can be used to deliver therapeutic molecules, such as CRISPR-Cas9 enzymes and gRNAs, to any tissue of choice. Tissue specificity can be achieved by attaching homing peptides to the sEV surface, such as attaching a homing peptide to a carbonyl residue on the sEV surface, such as non-canonical amino acids (ncAAs) in CD81 on the sEV surface. More than 100 homing peptides for more than 30 tissues and pathological cells can be used in the sEVs provided herein. Importantly, homing peptides not only direct sEVs (such as DMEs) to the intended target tissues but also decrease accumulation of sEVs (such as DMEs) in non-target tissues, thereby minimizing off-target effects.

[0069] A small extracellular vesicle (sEV) containing a tissue homing peptide attached to the sEV is provided. The sEV can be derived from mammalian milk, or can comprise a size, morphology, and bioavailability equivalent to an sEV derived from mammalian milk.

[0070] A "tissue homing peptide7’ as used herein refers to a peptide that, upon administration to a subject, migrates to and is delivered to a specific type of cells (such as a neuron), a specific tissue (such as the hippocampus), or a specific organ (such as the brain, the heart, or the pancreas) in the subject as opposed to being delivered nonspecifically and systemically. When attached to a molecule such as an sEV, the tissue homing peptide directs the molecule (such as an sEV) to the cell, tissue, or organ of interest.

[0071] Attachment of the tissue homing peptide enables the accumulation of sEVs in target tissues with great specificity. sEVs provided herein can have any suitable homing peptides, including any of the about 100 peptides that have been identified to serve as homing signals for 30 tissues. sEVs can have more than one homing peptide that direct sEVs to the same or different tissue. For example, sEVs can have 2, 3, 4, 5, or more homing peptides, such as 2, 3, 4, 5, or more brain homing peptides. 2, 3, 4, 5, or more neuron homing peptides, 2. 3, 4, 5, or more hippocampus homing peptides, a brain homing peptide and a neuron homing peptide, a brain homing peptide and a hippocampus homing peptide, a neuron homing peptide and a hippocampus homing peptide, a brain homing peptide, a neuron homing peptide, and a hippocampus homing peptide, 2, 3, 4, 5, or more heart homing peptides, or 2, 3, 4, 5, or more pancreas homing peptides. Two or more tissue homing peptides may have a synergistic effect in driving and delivering the sEVs to the target cell, tissue, or organ.

[0072] The tissue homing peptide can contain a carbonyl-reactive peptide, and bind covalently to a carbonyl residue on the sEV surface. The tissue homing peptide that is steered to any tissue or organ of interest can be used in the present disclosure. For example, the tissue2025-132-02homing peptide can be a brain homing peptide, a neuron homing peptide, a hippocampus homing peptide, a heart homing peptide, or a pancreas homing peptide. In additional embodiments, the homing peptide directs sEVs to lung or liver (such as hepatocytes), or to pathological cells including but not limited to glioma, thereby enabling selective delivery to these tissues and cell types. In some embodiments, the tissue homing peptide is a brain homing peptide and is derived from a rabies virus glycoprotein (RVG). In some embodiments, the tissue homing peptide is a neuron homing peptide and comprises Tetl. In some embodiments, the tissue homing peptide comprises a rabies virus glycoprotein (RVG)-derived peptide and Tetl. Without wishing to be bound by theory', RVG-derived peptide and Tetl can have a synergistic effect in directing and delivering sEVs to neurons or the brain. In some embodiments, the homing peptide is a lung homing peptide and comprises CTSTRKKQC (SEQ ID NO: 4). In some embodiments, the homing peptide is a liver (hepatocyte) homing peptide and comprises RDEAKRF (SEQ ID NO: 5). In some embodiments, the homing peptide is a cancer homing peptide, such as a glioma homing peptide and comprises CooP or apoliprotein E (apoE). In some embodiments, CooP comprises the ammo acid sequence of CGLSGLGVA (SEQ ID NO: 9).

[0073] In some embodiments, the tissue homing peptide is a hippocampus homing peptide and comprises the amino acid sequence of CDAGRKQKC (SEQ ID NO: 1). In some embodiments, the tissue homing peptide is a heart homing peptide and comprises the amino acid sequence of CRPPR (SEQ ID NO: 2). In some embodiments, the tissue homing peptide is a pancreas homing peptide and comprises the amino acid sequence of LSALPRT (SEQ ID NO: 3). In some embodiments, the tissue homing peptide is a lung homing peptide and comprises CTSTRKKQC (SEQ ID NO: 4). In some embodiments, the tissue homing peptide is a liver homing peptide and comprises RDEAKRF (SEQ ID NO: 5).

[0074] sEVs can be loaded with any cargo, including CRISPR-Cas9 and guide RNA. proteins (such as therapeutic proteins), plasmids (such as plasmids encoding therapeutic proteins), and small interfering RNA. In some embodiments, the gene editing agent includes a CRISPR-Cas9 enz me and a guide RNA that targets a gene of interest. In some embodiments, the plasmid encodes SYNGAP1 or MAGEL2. Protocols are available for loading EVs. including sEVs, with CRISPR-Cas9 and guide RNA (to edit genes), proteins and plasmids (to deliver genes), and small interfering RNA (to silence genes). Moreover, sEV payloads retain biological activity. For example, Cre recombinase included in sEVs caused recombination events in reporter mice. Chemotherapeutics, loaded into sEVs, slowed tumor2025-132-02growth and increased survival in murine xenograft models of human cancer; Further.CRISPR / Cas9-loaded DMEs can knock down IDH1(R132H) protein expression in malignant glioma U-87 cells. Thus, in some embodiments, DMEs are used in editing oncogenic alleles in cancer cells where tumor-homing peptides are available.

[0075] The sEV can further contain a detectable label. The detectable label can contain a fluorophore dye, a chemiluminescent dye, and / or a pH-sensitive dye.

[0076] The sEV further comprises a peptide that inhibits or reduces endocytosis or degradation. Such a peptide can be referred to as a "Don't-eat-me" peptide. For example, a CD47 peptide can be a ‘'Don’t-eat-me” peptide and can be attached to the sEV.

[0077] sEVs provided herein have characteristics suited for delivering therapeutic payloads to recipient cells. sEVs protect their cargo against degradation in the gastrointestinal tract and industrial processing. Animal studies show that about 50% of orally administered sEVs are absorbed, and oral bioavailability of sEV cargo has been demonstrated in humans. In addition to crossing the intestinal barrier, sEVs also cross barriers like vascular endothelial cells, placenta, and the blood-brain barrier. The intestinal mucosa, liver, and brain are the primary accumulation sites of orally administered sEVs, such as MEs. sEVs can be delivered to a tissue or organ of interest by attaching a tissue homing peptide to sEVs. Furthermore, sEVs (such as MEs) are biologically safe. Studies have shown that sEVs (such as MEs) are not immunogenic and do not elicit adverse reactions. They did not elicit a cytokine storm in human plasma following oral administration and in human peripheral blood mononuclear cells ex vivo. MEs did not elicit an immune response or impair liver and kidney function and erythropoiesis in rats. MEs did not cause liver or kidney damage and did not alter food and water intake or physical activity in mice.

[0078] The sEVs and related methods provided herein provide clinicians with a versatile tool for editing genes by CRISPR-Cas9 (prevention and cure of disease), delivering genes in the form of plasmids and proteins (treatment of disease), and silencing genes by small interfering RNA (treatment of disease) in any tissue of choice. The sEVs provided herein enable preventing, treating, and curing disease in any tissue with any payload with heretofore unknown specificity. This applies to both common and rare diseases.

[0079] Also provided is a pharmaceutical composition containing a therapeutically effective amount of the sEV provided herein.

[0080] The sEVs and sEV compositions provided herein can comprise lyophilized sEVs and / or a preservative. The preservative can be trehalose, such as 3% trehalose. The2025-132-02carbohydrate trehalose is the gold standard of cryoprotection of sEVs in pharmaceutical applications. Trehalose has received Generally Recognized As Safe status from the FDA. Purified MEs can be preserved during lyophilization through the addition of 3% trehalose, which improves ME storage and facilitates the distribution of sEVs in regions with poor medical infrastructure. As shown in FIGs. 17A and 17B, a final concentration of 3% or more trehalose in sEVs preserves sEVs when lyophilized for storage and shipping in powdered form.

[0081] In embodiments, sEV compositions are authenticated and characterized in accordance with criteria recommended by the International Society for Extracellular Vesicles (ISEV), for example showing positive markers CD9, CD63, CD81, HSP70, Alix, TsglOl, and the absence of negative markers including apolipoprotein B-100, (3-integrin, histone H3, and butyrophilin; casein micelles are not detectable in authenticated preparations.B. Delivering therapeutic molecules to target tissue using sEVs

[0082] A method of delivering a therapeutic molecule to a target tissue or a target organ in a subject is provided. The method includes administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a tissue homing peptide attached to the sEV and the therapeutic molecule.

[0083] The sEV can be derived from mammalian milk, or can comprise a size, morphology, and bioavailability equivalent to an sEV derived from mammalian milk.

[0084] Any tissue homing peptide of interest can be attached to sEVs. Attachment of the tissue homing peptide enables targeted delivery of sEVs to the tissue or organ of interest. In some embodiments, the tissue homing peptide includes a carbonyl-reactive peptide, and binds covalently to a carbonyl residue on the sEV surface. For example, the tissue homing peptide can be a brain homing peptide, a neuron homing peptide, a hippocampus homing peptide, a heart homing peptide, or a pancreas homing peptide. In other embodiments, the tissue homing peptide can be a lung homing peptide or a liver (hepatocyte) homing peptide, enabling targeted pulmonary or hepatic delivery, respectively, while reducing accumulation in nontarget tissues.

[0085] In some embodiments, the tissue homing peptide is a brain homing peptide and is derived from a rabies virus glycoprotein (RVG). In some embodiments, the tissue homing peptide is a neuron homing peptide and comprises Tetl. In some embodiments, the tissue homing peptide comprises a rabies virus glycoprotein (RVG)-derived peptide and Tetl.2025-132-02RVG-derived peptide and Tetl can have a synergistic effect in directing and delivering sEVs to neurons or the brain. In some embodiments, sEVs decorated with both Tetl and RVG exhibit enhanced brain accumulation relative to vehicle controls.

[0086] In some embodiments, the tissue homing peptide is a hippocampus homing peptide and comprises the amino acid sequence of CDAGRKQKC (SEQ ID NO: 1). In some embodiments, the tissue homing peptide is a heart homing peptide and comprises the amino acid sequence of CRPPR (SEQ ID NO: 2). In some embodiments, the tissue homing peptide is a pancreas homing peptide and comprises the amino acid sequence of LSALPRT (SEQ ID NO: 3). In embodiments directed to pulmonary delivery, DMEs decorated with a lung homing peptide comprising CTSTRKKQC (SEQ ID NO: 4) selectively accumulated in the lung following a single oral dose of approximately 1 x IO10DMEs / g, with no significant accumulation observed in spleen, brain, pancreas, kidneys, skeletal muscle, or gonads at 12 hours post administration.

[0087] In embodiments directed to hepatic delivery, DMEs decorated with a hepatocyte homing peptide comprising RDEAKRF (SEQ ID NO: 5) selectively accumulated in liver following a single oral dose of approximately 1 x IO10DMEs / g under otherwise identical conditions.

[0088] In cross-species studies, oral administration of DMEs loaded with a plasmid encoding near-infrared fluorescent protein and decorated with Tetl and RVG resulted in detectable fluorescence in neuronal cells of porcine brain, but not in spleen, demonstrating tissue specificity and functional deliver}’ across species.

[0089] For example, provided is a method of delivering a therapeutic molecule to the brain of a subject by administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a brain homing peptide (such as an RVG-derived peptide) attached to the sEV and the therapeutic molecule. Also provided is a method of delivering a therapeutic molecule to the neuron of a subject by administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a neuron homing peptide (such as Tetl), and optionally a brain homing peptide (such as the RVG-derived peptide), attached to the sEV and the therapeutic molecule. Also provided is a method of delivering a therapeutic molecule to the hippocampus of a subject by administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a hippocampus homing peptide (such as CDAGRKQKC (SEQ ID NO: 1)) attached to the sEV and the therapeutic molecule. Also provided is a method of delivering a therapeutic molecule to the heart of a subject by2025-132-02administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a heart homing peptide (such as CRPPR (SEQ ID NO: 2)) attached to the sEV and the therapeutic molecule. Also provided is a method of delivering a therapeutic molecule to the pancreas of a subject by administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a pancreas homing peptide (such as LSALPRT (SEQ ID NO: 3)) attached to the sEV and the therapeutic molecule.

[0090] sEVs can be loaded with any cargo, including CRISPR-Cas9 and guide RNA, proteins (such as therapeutic proteins), plasmids (such as plasmids encoding therapeutic proteins), and small interfering RNA. In some embodiments, the gene editing agent includes a CRISPR-Cas9 enzyme and a guide RNA that targets a gene of interest. In some embodiments, the plasmid encodes SYNGAP1 or MAGEL2. Protocols are available for loading EVs, including sEVs, with CRISPR-Cas9 and guide RNA (to edit genes), proteins and plasmids (to deliver genes), and small interfering RNA (to silence genes). In specific embodiments, methods provided herein deliver gene editing agents, such as a Cas9 enzyme and a guide RNA targeting a gene of interest, to a target tissue or organ to edit (for example, knock out) the gene of interest in the target tissue or organ.

[0091] Moreover, sEV payloads retain biological activity. For example, Cre recombinase included in sEVs caused recombination events in reporter mice. Chemotherapeutics, loaded into sEVs, slowed tumor growth and increased survival in murine xenograft models of human cancer.

[0092] In some embodiments, the sEV further comprises a detectable label. The detectable label can include a fluorophore, a chemiluminescent dye, a pH-sensitive dye, or a combination thereof.C. Treating diseases using sEVs

[0093] Provided herein is a method of treating a subject having a disease. The method includes administering a therapeutically effective amount of the sEV or the pharmaceutical composition provided herein. sEVs can be attached to a tissue homing peptide for targeted delivery to the tissue or organ of interest. sEVs provided herein can be loaded with cargo, such as a therapeutic agent, and delivered to any tissue of interest, for example to treat a disease or condition, including common diseases and rare diseases. In certain embodiments, the disease is a cancer such as glioblastoma multiforme, and sEVs decorated with glioma2025-132-02homing peptides (e.g., CooP or apoE) localize to tumors following systemic administration, with only trace distribution to surrounding healthy cells in xenograft models.

[0094] In some embodiments, the method includes administering a therapeutically effective amount of a small extracellular vesicle (sEV) comprising a tissue homing peptide attached to the sEV and a therapeutic molecule, wherein the sEV delivers the therapeutic molecule to a target tissue or organ affected by the disease. In some embodiments, the disease is glioblastoma multiforme, SYNGAP1 haploinsufficiency, a MAGEL2-associated disease, heart disease, or a rare disease.

[0095] In specific embodiments, methods provided herein for treating a disease include administering sEVs containing gene editing agents, such as a Cas9 enzyme and a guide RNA targeting a gene of interest, to a subject for delivery to the target tissue or organ to edit (for example, knock out) the gene of interest in the target tissue or organ.

[0096] For example, provided is a method of treating a disease in the brain of a subject by administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a brain homing peptide (such as an RVG peptide) attached to the sEV and the therapeutic molecule. Also provided is a method of treating a disease of the neuron of a subject by administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a neuron homing peptide (such as Tetl), and optionally a brain homing peptide (such as the RVG-derived peptide), attached to the sEV and the therapeutic molecule. Also provided is a method of treating a disease in the hippocampus of a subject by administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a hippocampus homing peptide (such as CDAGRKQKC (SEQ ID NO: 1)) attached to the sEV and the therapeutic molecule. Also provided is a method of treating a disease of the heart of a subject by administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a heart homing peptide (such as CRPPR (SEQ ID NO: 2)) attached to the sEV and the therapeutic molecule. Also provided is a method of treating a disease of the pancreas of a subject by administering a therapeutically effective amount of a small extracellular vesicle (sEV) containing a pancreas homing peptide (such as LSALPRT (SEQ ID NO: 3)) attached to the sEV and the therapeutic molecule. In further embodiments, the disease affects pulmonary or hepatic tissue, and the sEV is decorated, respectively, with a lung homing peptide (CTSTRKKQC, SEQ ID NO: 4) or a hepatocyte homing peptide (RDEAKRF, SEQ ID NO: 5) to increase accumulation in the target tissue and reduce off-target distribution.2025-132-02

[0097] For example, the sEVs can be used to treat glioblastoma multiforme (GBM).Treatment of GBM using the sEVs serves as one example of how the sEVs provided herein can be applied in the treatment of a common disease with poor prognosis. Despite the availability of 13 Food and Drug Administration (FDA)-approved drugs to treat brain tumors, an estimated 18,000 of the 24,000 Americans diagnosed (75%) with malignant brain tumors died from the disease in 2020. GBM is the most common malignant intracranial tumor, accounting for approximately 30% of primary brain tumors, and has a median survival of only 10-14 months with no more than 5% of patients surviving more than three years.Peptides have been identified that direct nanoparticles to GBM tumors, such as the apoE or CooP peptides. In some embodiments, CooP comprises the amino acid sequence of CGLSGLGVA (SEQ ID NO: 9). sEVs provided herein, modified through the covalent attachment of apoE or CooP, accumulate in the brain and deliver their payloads to tumors. Payloads can target, for example, mutations in the isocitrate dehydrogenase 1 (IDH1) gene. Mutations in IDH1 occur in the vast majority of glioma, and the R132H mutation is the most common among IDH1 mutations. Examples of sEV payloads include IDH1 siRNA to knock down the expression of the oncogenic mutant IDH1 allele (without affecting the expression of the wild-type allele) and CRISPR-Cas9 proteins and guide RNA to edit the mutant allele.

[0098] The sEVs provided herein can be used to treat heart disease. Heart disease is the leading cause of death for people in the U.S. and is poised to benefit from advances in nanomedicine. Approximately 655,000 Americans die from heart disease every year and costs related to the disease are high - roughly $219 billion annually. The use of RNA therapeutics holds great promise in preventing and treating heart disease. In the context of cardiovascular disease, the use of RNA therapeutics is being explored in the treatment of hypercholesterolemia, hypertriglyceridemia, cardiac amyloidosis, and atrial fibrillation. Twenty RNA therapeutics for reducing risk factors leading to cardiovascular disease were undergoing testing in randomized clinical trials, Phases 1 through 3, in 2018, and five RNA treatments received FDA approval by 2018. A search of NIH’s ClinicalTrials.gov database using the search terms '‘heart disease” and “RNA” retrieved 837 clinical trials. The use of RNA therapeutics in the treatment of heart disease faces the same challenges as the use of RNA therapeutics to treat any other disease, including RNA degradation by circulating nucleases, non-target effects, and release of pro-inflammatory cytokines induced by siRNAs through toll-like receptor signaling pathways. Encapsulation of RNA therapeutics in sEVs modified with homing peptides eliminates or minimizes these challenges.2025-132-02

[0099] In addition to treating patients with common diseases such as GBM, Alzheimer’s disease, and pancreatic cancer, the sEVs provided herein can be used to treat an underserved group of patients, i.e., individuals suffering from rare diseases. Diseases are considered rare in the U.S. if affecting fewer than 200,000 patients. Collectively, rare diseases affect approximately 30 million people in the U.S. Well-known examples include cystic fibrosis (lung), Huntington’s disease (brain). SYNGAP1 haploinsufficiency (brain), and Duchenne muscular dystrophy (muscle). As the majority of rare diseases arise from genetic disorders, gene therapy is a potentially rewarding option for treating and curing them. Treatment can be achieved by delivering mRNA, plasmids, or proteins to target tissues, whereas cure can be achieved by delivering gene-editing tools (CRISPR-Cas9 proteins and nucleic acids) to target tissues. For at least 24 rare diseases, the delivery of RNA therapeutics, such as gene silencing by siRNA and gene editing by CRISPR-Cas9, to sites of disease is considered a viable approach to treatment and cure, including cystic fibrosis, Huntington’s disease, and Duchenne muscular dystrophy. Homing peptides are known for the sites in which these diseases reside, i.e., lung, brain, and muscle. The peptide-modified sEVs provided herein, loaded with RNA therapeutics, can treat these diseases and improve the quality of life of persons suffering from rare diseases without requiring major follow-up investments in developing disease-specific drugs.

[0100] For example, the sEVs provided herein can be used to treat SYNGAP1 haploinsufficiency. SYNGAP1 haploinsufficiency is a rare disease with an incidence of 1-4 in 10,000 individuals. SYNGAP1 haploinsufficiency causes neurodev el opmental disorders defined by autistic traits, cognitive impairment, and epilepsy. The sEVs provided herein can deliver the SYNGAP1 gene or a plasmid encoding SYNGAP1 to the brain, thereby benefiting patients suffering from SYNGAP1 haploinsufficiency.

[0101] The sEVs provided herein can be used to treat MAGEL2-associated disease. The sEVs provided herein can deliver the MAGEL2 gene or a plasmid encoding MAGEE2 to the brain (for example hypothalamus), thereby benefiting patients suffering from SYNGAP1 haploinsufficiency. MAGEL2-associated disease can include, without limitation, Prader-Willi syndrome, Angelman syndrome, Schaaf-Yang Syndrome, and Distal Arthrogry posis with Hypopituitarism. Intellectual Disability, And Facial Anomalies.

[0102] The combination of a genetically engineered mammary cell line with bioorthogonal chemistry to produce sEVs for the prevention, treatment, and cure of diseases as provided herein is conceptually novel. First, conventional protocols attached a single homing peptide2025-132-02to nanoparticles, i.e., clinicians were not provided with the flexibility of the technology discussed here.

[0103] Due to the versatile nature of the sEVs, the sEVs provided herein can be used in the prevention, treatment, and cure of disease in which the delivery of therapeutic pay loads by nanoparticles is desirable and tissue homing peptides are available. The sEVs are useful for common (such as GBM, cardiovascular disease, Alzheimer’s disease) and rare diseases.D. Producing modified small extracellular vesicles

[0104] Provided herein is a method of producing a modified small extracellular vesicle (sEV). The method includes attaching a carbonyl-reactive peptide to a carbonyl residue on the sEV surface. The carbonyl-reactive peptide can be a tissue homing peptide.

[0105] In some embodiments, the tissue homing peptide is a brain homing peptide, a hippocampus homing peptide, a neuron homing peptide, a heart homing peptide, or a pancreas homing peptide.

[0106] In some embodiments, the tissue homing peptide is a brain homing peptide and is derived from rabies virus glycoprotein (RVG). In some embodiments, the tissue homing peptide is a neuron homing peptide and comprises Tetl. In some embodiments, the tissue homing peptide comprises a rabies virus glycoprotein (RVG)-derived peptide and Tetl. RVG-derived peptide and Tetl can have a synergistic effect in directing and delivering sEVs to neurons or the brain.

[0107] In some embodiments, the tissue homing peptide is a hippocampus homing peptide and comprises the amino acid sequence of CDAGRKQKC (SEQ ID NO: 1). In some embodiments, the tissue homing peptide is a heart homing peptide and comprises the amino acid sequence of CRPPR (SEQ ID NO: 2). In some embodiments, the tissue homing peptide is a pancreas homing peptide and comprises the amino acid sequence of LSALPRT (SEQ ID NO: 3).

[0108] The method can further include loading cargo onto the sEV. Any cargo can be loaded onto the sEV. In some embodiments, the cargo comprises a gene editing agent, a protein, a plasmid, or a small interfering RNA. In some embodiments, the gene editing agent comprises a CRISPR-Cas9 enzyme and a guide RNA. In some embodiments, the plasmid encodes SYNGAP1 or MAGEL2.

[0109] In embodiments, the sEV compositions include exosomes purified from milk and synthetic carbonyl-reactive peptides attached to the exosomes.2025-132-02

[0110] In embodiments, the sEV compositions provided herein can be produced by purifying exosomes from milk, and attaching homing peptides, such as synthetic carbonylreactive peptides, to the exosomes.

[0111] The compositions and methods provided herein can be used for delivery of therapeutic molecules to a target tissue or organ of interest, and for treatment and prevention of various diseases and conditions, including therapeutic delivery, regenerative delivery, and vaccine development.

[0112] The compositions and methods provided herein afford clinicians a novel tool for treating diseases, including the rare diseases.

[0113] The sEVs and sEV compositions provided herein can comprise lyophilized sEVs and / or a preservative. The preservative can be trehalose, such as 3% trehalose. The carbohydrate trehalose is the gold standard of cryoprotection of sEVs in pharmaceutical applications. Trehalose has received Generally Recognized As Safe status from the FDA. Purified MEs can be preserved during lyophilization through the addition of 3% trehalose, which improves ME storage and facilitates the distribution of sEVs in regions with poor medical infrastructure. As shown in FIGs. 17A and 17B, a final concentration of 3% or more trehalose in sEVs preserves sEVs when lyophilized for storage and shipping in powdered form.

[0114] In embodiments, tissue homing or “Don’t-eat-me” peptides are engineered to include a poly -histidine tag (His6) flanked by spacers (GSG-HHHHHH-GSG, SEQ ID NO: 6), enabling affinity capture of modified sEVs on Ni2+-charged resin and release by sequential imidazole washes at yields of approximately 5 * 108DMEs per 250 pL of resin; addition ofHis6 does not alter homing functionality.

[0115] DME preparations can be sterilized by combining 0.22-pm membrane filtration with high-pressure processing (e.g., 600 bar, 180 seconds, 10-16°C), which can eliminate microbial growth without reducing DME counts. Endotoxin levels can be controlled by using molecular biology grade w ater and disposable plasticware; DME preparations have measured endotoxin levels of approximately 0.05 EU / mL, below acceptance levels recognized by regulatory' authorities.

[0116] The methods of producing DMEs provided herein can further include capturing the sEV on a Ni2+-charged affinity resin, and purifying the sEVs. The method can further include sterilizing the sEV by filtration through a membrane filter followed by high-pressure processing.2025-132-02

[0117] In embodiments directed to stability during distribution, DME suspensions preserved with about 3% trehalose remain functional following freezing, shipping on dry ice, and storage at -80°C, as evidenced by successful oral delivery and brain accumulation in animal models.EXAMPLESExample 1: Delivery of sEVs attached with homing peptide to the target tissue

[0118] This example describes the accumulation of DMEs attached to a tissue homing peptide in the target tissue. A hippocampus homing peptide, a heart homing peptide, and a pancreas homing peptide were each attached to DMEs, and were administered to mice by tail vein injection.

[0119] Hippocampus. A hippocampus homing peptide (CDAGRKQKC) (Toome K. Tartu, Estonia: University of Tartu: 2020) was attached to fluorophore-labeled (Khanam et al. Am J Physiol Cell Physiol 202E32EC607-C14) DMEs. The DMEs (1011DMEs / g) were administered by tail vein injection to C57BL / 6J mice. As shown in FIG. 1A, after three hours post tail vein injection, accumulation of homing peptide-attached DME was reduced in nontarget tissues to near-background levels while accumulation of homing peptide-attached DME increased in the brain. As shown in FIG. IB, within the brain, DME accumulated specifically in the hippocampus, whereas DME levels were modest in the cortex and cerebellum.

[0120] Heart. A heart homing peptide (CRPPR) (Zhang et al. Biomaterials2008;29( 12): 1976-88) was attached to fluorophore-labeled DMEs. The DMEs (1011DMEs / g) were administered by tail vein injection to C57BL / 6J mice. As shown in FIG. 2, after three hours post tail vein injection, peptide decoration reduced accumulation of DME in non-target tissues to near-background levels while increasing DME accumulation in the heart.

[0121] Pancreas. A pancreas homing peptide (LSALPRT) (Kim et al. J Ind Eng Chem 2017;45:404-411) was attached to fluorophore-labeled DMEs. The DMEs (1011DMEs / g) were administered by tail vein injection to C57BL / 6J mice. As shown in FIG. 3, after three hours post tail vein injection, peptide decoration reduced accumulation of DME in non-target tissues to near-background levels while increasing DME accumulation in the pancreas.

[0122] Brain. A brain homing peptide derived from Rabies Virus Glycoprotein ( RVG peptide7’) was attached to fluorophore-labeled DMEs. DMEs (1011DMEs / g) with or without the homing peptide were administered by tail vein injection to C57BL / 6J mice. As shown in2025-132-02FIG. 4A, RVG peptide-attached DMEs selectively accumulated in the brain as compared to DMEs without homing peptide. As shown in FIG. 4B, RVG peptide-attached DMEs selectively accumulated in the cortex and cerebellum.

[0123] Neurons. The effects of a neuron homing peptide were assessed. Tetl steers nanoparticles to neurons in the brain, but only if combined with a brain homing peptide. Tetl (HLNILSTLWKYR) (SEQ ID NO: 7) and a brain homing peptide derived from RVG (‘ RVG peptide”) (YTIWMPENPRPGTPCDIFTNSRGKRASNG) (SEQ ID NO: 8) were attached to fluorophore-labeled DMEs. DMEs (1011DMEs / g) with or without the homing peptides were administered by tail vein injection to C57BL / 6J mice. As shown in FIGs. 8A-8B, the combination of Tetl and RVG caused a substantial accumulation of DMEs in the brain, including cortex and cerebellum. In FIG. 8A, the vehicle administered group showed the highest HiLyte™ Fluor signal in all organs except the brain, while the Tetl+RVG-administered group exhibited enhanced brain targeting.

[0124] Luns. The delivery of DMEs to the lung was assessed. A lung homing peptide (CTSTRKKQC) (SEQ ID NO: 4) was synthesized with an N-terminal acetylation, an internal GSG-HHHHHH-GSG (spacer-His6-spacer, SEQ ID NO: 6) tag, and a C-terminal hydrazide modification (purity: 95.6%). The lung homing peptide was attached to EliLyte™ Fluor 750-labeled bovine milk exosomes (BMEs) to produce lung-targeting DMEs (L-DMEs). A single oral dose of approximately 1 x IO10DMEs / g was administered to mice (N=2 per group). Six groups were assessed: PBS control, lung peptide buffer control without exosomes (L-Buffer), hepatocyte peptide buffer control without exosomes (He-Buffer), homing-peptide-free BMEs tagged with HiLyte™ Fluor 750 (BMEs), BMEs tagged with lung peptide and HiLyte™ Fluor 750 (L-DMEs), and BMEs tagged with hepatocyte peptide and HiLyte™ Fluor 750 (He-DMEs). Tissues were harvested 12 hours after administration. As show n in FIG. 9, L-DMEs selectively accumulated in the lung, whereas no significant accumulation was observed in the spleen, brain, pancreas, kidneys, skeletal muscle, or gonads, demonstrating lung-specific targeting by DMEs decorated with the lung homing peptide.

[0125] Liver. The delivery of DMEs to the liver was assessed. A hepatocyte homing peptide (RDEAKRF) (SEQ ID NO: 5) was synthesized with an N-terminal acetylation, an internal GSG-HHHHHH-GSG (spacer-His6-spacer, SEQ ID NO: 6) tag, and a C-terminal hydrazide modification (purity: 98.6%). The hepatocyte homing peptide was attached to HiLyte™ Fluor 750-labeled BMEs to produce hepatocyte-targeting DMEs (He-DMEs). A single oral dose of approximately 1 x 1010DMEs / g was administered to mice (N=2 per group) using the same2025-132-02six-group design described above for the lung study. Tissues were harvested 12 hours after administration. As shown in FIG.9. He-DMEs selectively accumulated in the liver, whereas no significant accumulation was observed in the spleen, brain, pancreas, kidneys, skeletal muscle, or gonads (including male and female gonads), demonstrating liver-specific targeting by DMEs decorated with the hepatocyte homing peptide.

[0126] Pathological cells (glioma). The specificity of DMEs for pathological cells was assessed. Glioblastoma multiforme (GBM) is among the deadliest forms of cancer.Fluorophore-labeled DMEs were decorated with glioma homing peptides, CooP or apoE, and were administered by tail vein injection to a male mouse xenograft model of human GBM at a dose of 0.25 x 1014DMEs / kg. As shown in FIG. 10, glioma homing peptide-decorated DMEs co-localized with tumors whereas only traces of DMEs were detectable in surrounding healthy cells, demonstrating the specificity of the DME delivery system for pathological cells.

[0127] Reduction of macrophage elimination. sEVs (e.g., MEs, BMEs) can be rapidly eliminated by macrophages. When fluorophore-labeled DMEs were decorated with a “Don’t-eat-me'’ peptide, CD47, their internalization by murine bone marrow-derived macrophages ex vivo was approximately 50% lower compared to CD47-negative DMEs. The deceleration of DME elimination by CD47 was even more pronounced in vivo. As shown in FIG. 11A, plasma levels of CD47-positive DMEs were 12.3-fold higher than levels of CD47-negative DMEs two hours after administration by tail vein injection in female mice. As shown in FIG.11B, slow elimination was associated with an increase in DME accumulation in the brain following nasal administration at a dose of 4.1 x 1010DMEs / kg, demonstrating increased therapeutic potency of DMEs decorated with a Don’t-eat-me peptide.Example 2: sEV-mediated delivery of therapeutic agents to target tissues

[0128] FIG. 5 depicts In Vivo Imaging System (IVIS) images (EGFP channel) of the tissues after single oral delivery of milk exosomes (MEs) loaded with a plasmid encoding EGFP and MAGEL2 in mice. The mice were administered a single oral dose of 1.7 x 1010MEs per g body weight. Images were captured 72 hours after treatment. MAGEL2-loaded MEs accumulated in the brain. FIG. 6 depicts IVIS images (EGFP channel) of the tissues after repeated oral delivery of an EGFP-MAGEL2 plasmid-loaded MEs in mice. The mice were administered repeated oral doses of 1.7 x 1010MEs per g body weight per dose on days 1, 3, and 5. Images were captured on day 7. MAGEL2-loaded MEs accumulated in the brain. In sum, as shown in FIGs. 5 and 6, MAGEL2-loaded MEs accumulated in the brain after single2025-132-02or repeated oral administration. Delivery of MAGEL2-loaded MEs attached to tissue homing peptide is studied.Example 3: sEV-mediated Delivery of gene editing agents to target tissues

[0129] This example describes delivery of gene editing agents to target cells and organs using DMEs.

[0130] EGFP reporter cells. EGFP gRNAs (addgene 51760 and 51763) were loaded onto Cas9 endonuclease (“Cas9”)-positive DMEs and delivered to mammary epithelial EGFP reporter cells (Creative Biogene, CSC-RR0515). As shown in FIG. 7A, EGFP fluorescence was diminished substantially in EGFP reporter cells to which Cas9 and EGFP gRNA were delivered as compared to control cells to which Cas9 and EGFP gRNA were not delivered 9 days after initiation of culture, indicating successful delivery of the gene editing agents and editing of EGFP.

[0131] EGFP reporter mice. The delivery of genome editors by DMEs was further demonstrated in a whole organism. EGFP gRNAs were loaded onto Cas9-positive DMEs and delivered to EGFP reporter mice (Jackson Labs, strain #: 006567) by intravenous injection. The DMEs w ere decorated with homing peptide for brain, heart, or pancreas. Tissues were harvested and perfused prior to analysis of EGFP fluorescence. As shown in FIG. 7B, EGFP fluorescence was eclipsed in target tissues from mice treated with gRNA and Cas9-loaded DMEs, indicating successful delivery of gene editing agents to the target tissues and editing of EGFP, whereas EGFP fluorescence remained strong in non-target tissues.

[0132] IDH1 knockdown in glioma cells. The delivery of gene editing agents by DMEs was further demonstrated in malignant glioma cells. Mutations in isocitrate dehydrogenase 1 (IDH1) occur in the vast majority7of low er-grade gliomas, and the most common mutation (CGT>CAT) affects codon 132, causing an arginine (R) to histidine (H) change in 1DH1(R132H). DMEs were loaded with an IDH1 CRISPR / Cas9 plasmid (Santa Cruz Biotechnology sc-401159) encoding Cas9 and three gRNAs targeting the CAT allele, and malignant glioma U-87 cells (ATCC HTB-14) were cultured with 10 pg DME protein / mL for 48 hours. As shown in FIG. 12, the expression of IDH1 protein decreased by approximately 61% compared to cells cultured with naive MEs, demonstrating that DMEs can deliver functional gene editing agents to knock down the expression of an oncogenic mutant allele without affecting the wild-ty pe allele.2025-132-02Example 4: Restoration of gene expression by sEV-mediated delivery of a therapeutic gene

[0133] This example describes the restoration of SYNGAP1 protein expression to wild-type levels in Syngapl haploinsufficient mice by delivering a SYNGAP1 -encoding plasmid using MEs administered by nasal spray.

[0134] SYNGAP1 haploinsufficiency. SYNGAP1 haploinsufficiency is an ultra-rare disease in which patients and caregivers are underserved. Naive MEs were loaded with a plasmid encoding SYNGAP1 (SYNGAPl-pVAXl. 7,024 bp) and delivered by nasal spray to female Syngapl haploinsufficient mice (B6;129-SyngapltmlRlh / J; Jackson Labs, stock 008890). As shown in FIG. 13A, treatment with 0.7 x 1014DMEs / kg administered every other day for 14 days by nasal spray restored the expression of SYNGAP1 protein to wildtype levels in whole brains from Syngapl haploinsufficient mice. Controls included wild-type and haploinsufficient mice that were not treated with MEs, and wild-type and haploinsufficient mice treated with empty MEs. Brains were harvested three days after the final dose. As shown in FIG. 13B, a regimen of 0.7 x 1014DMEs / kg administered every7other day for 6 days was also effective in restoring SYNGAP1 protein expression.

[0135] The DME dosage required to achieve wild-type levels of SYNGAP1 protein expression was titrated. As shown in FIG. 13C, a single low dose of 1.5 x 1011DMEs / kg administered by nasal spray was sufficient to rescue SYNGAP1 protein expression to wildtype levels in the whole brains of Syngapl haploinsufficient mice. This observation is consistent with the fact that most neurogenesis is completed embryonically in the mammalian brain and continues after birth only in distinct regions of the brain or if induced by internal or external stimuli, i.e., plasmids are not diluted when cells do not divide.Example 7: Oral delivery of a therapeutic gene by sEVs

[0136] This example describes the oral delivery of MEs loaded with a plasmid encoding EGFP fused with MAGEL2, a protein implicated in Prader-Willi syndrome.

[0137] Naive MEs were loaded with a plasmid (size 9,915 bp) encoding EGFP fused with MAGEL2 and administered to female C57BL / 6J mice by oral gavage at a dose of 1.7 x 1013 DMEs / kg. As shown in FIG. 14A, the fusion protein was expressed in the brain following a single oral dose. The administration of a single, comparatively small dose of MEs was sufficient for detecting the fusion protein in the brain.2025-132-02

[0138] The same EGFP-MAGEL2 plasmid-loaded MEs were administered to female C57BL / 6J mice by oral gavage. Three doses of 1.7 x 1013 DMEs / kg each were administered on Days 1, 3, and 5, and brains were harvested on Day 7. As shown in FIG. 14B, repeated administration did not result in an additional increase in the expression of the fusion protein compared to a single dose, which is consistent with observations made for delivering the SYNGAP1 gene.Example 8: Cross-species delivery of sEVs in swine

[0139] This example describes cross-species validation of DME delivery in swine, demonstrating that findings gathered in mice are reproducible in pigs.

[0140] DMEs were functionalized through decoration with a neuron homing peptide (Tetl, SEQ ID NO: 7) and auxiliary peptide (RVG, SEQ ID NO: 8), and by loading a plasmid encoding near-infrared fluorescent protein (iRFP; iRFP-pVAXl; size 4,750 bp). Samples were frozen in the presence of 3% trehalose at the primary' study site (Lincoln, NE) and shipped overnight on dry ice to Davis. CA, where reagents were stored at -80°C for one week prior to administration. A relatively low dose of 2.5 x 1011 DMEs / kg was administered by syringe feeding to three-day-old male swine. Project personnel at both sites were blinded regarding group assignments. Controls received iRFP-pVAXl -free DMEs.

[0141] Tissues were harvested and shipped to the primary study site, and iRFP fluorescence was assessed in a LI-COR imaging system. As shown in FIG. 15A, fluorescence was evident in neuronal cells in the brains from the two piglets that received plasmid-loaded DMEs compared to control. As shown in FIG. 15B, no iRFP fluorescence was detectable in the spleen, demonstrating tissue specificity. These results demonstrate that DMEs retain functionality following freezing, shipping, and storage, and that the oral bioavailability and brain accumulation of DMEs observed in mice are reproducible in swine using a doubleblinded design.Example 9: Intrauterine delivery of sEVs across the placenta

[0142] This example describes the delivery of MEs and ME cargo across the placenta to murine embryos and placentas, demonstrating the potential for in utero gene therapy using sEVs.

[0143] Placental crossing and fetal accumulation. DiR-labeled MEs were administered orally to pregnant dams, and tissues were harvested on embryonic day 16.5 (24 hours after oral administration). As show n in FIG. 16A, DiR-labeled MEs accumulated in the embry o2025-132-02and placenta compared to unlabeled ME controls. MEs loaded with fluorophore (IRDye)-labeled miR-30d, transfected into MEs, were also administered orally, and tissues were harvested 6 hours after oral administration on embryonic day 16.5. As shown in FIG. 16B, IRDye-labeled miR-30d was detected in the embryo and placenta following ME-mediated delivery'. As shown in FIG. 16C, the same result was obtained using IRDye-labeled miR-21-5p, confirming that MEs can deliver small RNA cargo across the placenta. These results demonstrate that MEs cross the placenta and deliver payload to murine fetuses, indicating that DMEs may allow for the editing of genes in utero, which constitutes an advantage in the treatment of genetic diseases in which phenotypes may not be reversible if treatment is initiated after birth.Example 10: Storage stability and preservation of sEVs

[0144] This example describes the preservation of sEV count and functionality during storage using trehalose, and the preservation of tissue distribution patterns following lyophilization and freezing.

[0145] MEs were lyophilized in the presence of graded concentrations of trehalose and counted. As shown in FIG. 17A, a final concentration of 3% or more trehalose preserved sEVs when lyophilized for storage and shipping in powdered form.

[0146] In addition to preserving sEV count, trehalose at 3% preserved the tissue distribution patterns of DMEs, including the crossing of the blood-brain barrier. As shown in FIG. 17B, DMEs lyophilized in the presence of 3% trehalose retained their tissue distribution pattern, including accumulation in the brain, heart, and lung, when assessed three hours after tail vein injection in male mice at a dose of 1013DMEs / kg. These results demonstrate that trehalose-preserved DMEs retain functionality' and targeting specificity following lyophilization. Example 11: Sterilization of sEV preparations

[0147] This example describes a sterilization protocol for sEV preparations that eliminates microbial contamination without causing a decrease in sEV counts or a loss of sEV functionality.

[0148] Filtration and high pressure processing. High pressure processing (HPP) is a procedure for reducing pathogenic bacteria by 5 orders of magnitude. However, HPP does not inactivate all bacterial spores present in a sample, and the average size of spores is approximately 1 pm. DME preparations were filtered through a 0.22-pm membrane filter and the flow-through w as treated w ith HPP using potable water as pressurizing medium and a2025-132-02Hiperbaric 55L instrument (10 to 16°C, 600 bar, 180 seconds hold time). As shown in FIG.18A, membrane filtration through a 0.22-pm filter followed by HPP at about 600 bar for about 180 seconds at about 10-16°C caused an average loss of approximately 35 percent across three DME configurations (DMEs linked to heart, hippocampus, or pancreas homing peptides) when measured in a single technical run, consistent with acceptable processing attrition in exchange for microbial risk reduction.

[0149] As further shown in FIG. 18B, no microbial growth was detected on plates cultured under anaerobic conditions for bacteria and aerobic conditions for fungi following filtration plus HPP, using MRS agar for Gram-positive bacteria, LB agar for Gram-negative bacteria, and Sabouraud Dextrose agar for fungi; positive controls inoculated with Lactobacillus gasseri, Escherichia coh Nissle 1917, and Candida albicans yielded on the order of 107-108CFU, confirming culture sensitivity. Consistent with these observations, positive control plates yielded approximately 1.25 x 108colony forming units for Lactobacillus gasseri (Gram-positive) and 1.35 x io7colony forming units for Escherichia coli Nissle 1917 (Gram-negative) under the same plating conditions, confirming assay sensitivity and the effectiveness of 0.22-pm filtration plus HPP at about 600 bar for about 180 seconds at about 10-16°C.

[0150] These data corroborate the feasibility of combining 0.22-p.m filtration and HPP to eliminate detectable microbial contamination without compromising DME functional attributes elsewhere in the specification.

[0151] Endotoxin testing. DME preparations were tested using the Limulus amebocyte endotoxin test (Pierce™ Chromogenic Endotoxin Quant Kit), which has a sensitivity of 0.01 EU / mL and an assay range of 0.01 to 1.0 EU / mL. The endotoxin level in DME preparations was 0.05 EU / mL, which is below levels accepted by the FDA and regulatory agencies in Europe. Positive controls were prepared using non-disposable plasticware and tap water and contained detectable levels of endotoxin (2.1 to 2.4 EU / mL). Configuration-specific endotoxin testing using the Pierce™ Chromogenic Endotoxin Quant Kit (sensitivity 0.01 EU / mL; assay range 0.01-1.0 EU / mL) yielded values of 0.04 EU / mL for DMEs decorated with a heart homing peptide. 0.07 EU / mL for DMEs decorated with a hippocampus homing peptide, and 0.08 EU / mL for DMEs decorated with a pancreas homing peptide, consistent with the representative value reported above. Taken together, across configurations and production lots, endotoxin levels for DME preparations ranged from approximately 0.04 to 0.08 EU / mL. with representative lots measuring about 0.05 EU / mL. No endotoxin was2025-132-02detectable in the diluent control, whereas positive controls prepared using non-disposable plasticware and tap water contained 2.1-2.4 EU / mL.

[0152] Virological testing was conducted. Tables la and lb summarize measurements of avian flu virus (H5N1) and bovine diarrhea virus (BVDV) in preparations of bovine milk exosomes purified by ultracentrifugation (UC); size exclusion chromatography (SEC) and sucrose density gradient centrifugation (SDGC). Tests were conducted using real-time polymerase chain reaction (real-time PCR or qPCR). The reagents are manufactured in a certified, template-free environment. The H5N1- or BVDV- positive sample control was used in the set to identify false negative results. No H5N1 or BVDV was detected in the DME preparations.Table la. Measurement of avian flu virus (H5N1) in preparations of DMEsDME Configurations and Controls Ct valueaDME-heart homing peptide >40DME-hippocampus homing peptide >40DME-pancreas homing peptide >40Input material >40Positive control (non-disposable 2.1- 2.4plasticware and tap water)No template control >40aA Ct values < 35 is defined as positive for H5N1.Table lb. Measurement of bovine diarrhea virus (BVDV) in preparations of DMEs DME Configurations and Controls Ct value3DME-heart homing peptide >40DME-hippocampus homing peptide >40DME-pancreas homing peptide >40Virus-free control >40RNA pooled from 14 BVDV reference 25.6 ± 0.2strainsaA Ct values < 31 indicates a presumptive persistently infected BVDV.

[0153] These results demonstrate that DME preparations prepared using molecular biology' grade water and disposable plasticware contain low or undetectable levels of endotoxins and viral loads suitable for therapeutic use.2025-132-02Example 12: Affinity purification of modified sEVs using histidine tags

[0154] This example describes an affinity-based purification strategy for DMEs using a poly-histidine (His6) tag fused with homing peptides for capture on nickel resin, and demonstrates that the addition of His6 does not alter homing peptide functionality'.

[0155] Synthetic peptides were designed to include an internal poly -histidine tag (His6) flanked by spacers (GSG HHHHHH GSG) (SEQ ID NO: 6). DMEs were decorated with His6-tagged homing peptides, and the His6-tagged DMEs were purified using Ni2+resin. As shown in FIG. 24A, Ni2captured His6-tagged DMEs, which were released by two sequential imidazole washes at approximately 5 x 108DMEs per 250 pL Ni2+resin. By design, every' DME eluted off the Ni2+resin is decorated with the homing peptide fused with the His6 tag. Affinity' purification further decreases the heterogeneity of DME preparations.

[0156] Retained homing function. The addition of His6 to the homing peptide did not alter homing peptide functionality. As shown in FIG. 24B, DMEs decorated with a His6-tagged pancreas homing peptide localized to the pancreas at a dose of 1011 DMEs / kg in female mice, comparable to DMEs decorated with the pancreas homing peptide without the His6 tag. These results demonstrate that affinity purification using His6 / Ni2+chemistry can be used to prepare highly homogeneous DME populations without compromising homing specificity.

[0157] Peptide identity and purity analytics. Synthetic homing peptides used to decorate DMEs were qualified by HPLC and mass spectrometry, confirming sequence identity, expected theoretical molecular weights, and purity at or above approximately ninety-five percent with aqueous solubility' under the stated N-terminal acety lation, internal GSG His6 GSG spacer, and C-terminal hydrazide modifications; representative CRPPR (SEQ ID NO: 2), CDAGRKQKC (SEQ ID NO: 1), and LSALPRT (SEQ ID NO: 3) lots showed purities of about 99.2%, 96.3%, and 95.6%, respectively, as depicted in FIG. 25.Example 13: Homogeneity and authentication of sEV preparations

[0158] This example describes the assessment of DME homogeneity' during sequential purification and the authentication of ME starting material.

[0159] Homogeneity'. The sequential use of size exclusion chromatography (SEC), sucrose density gradient centrifugation (SDGC), and affinity' purification improved the homogeneity of DMEs. Immunoblot analysis was used to track the expression of an exosome marker, CD9, and a whey protein contaminant (beta-lactoglobulin) at every purification step. The relative abundance of marker proteins was assessed by gel densitometry using a LI-COR Odyssey2025-132-02imager, and readings were normalized by total protein and sample volume. As a reference, naive MEs purified by ultracentrifugation were used. As shown in FIG. 19A, CD9 was enriched 12.5-fold during the course of purification, whereas beta-lactoglobulin was no longer detectable by the end of purification. As shown in FIG. 19B, representative immunoblots confirmed the progressive enrichment of the exosome marker and removal of the whey protein contaminant. The results were the same for another exosome marker protein (CD81). These results demonstrate that the combined use of SEC, SDGC, and affinity purification enables the preparation of homogeneous DMEs, which is an important safety consideration because impure preparations will confound data on drug dosages.

[0160] Authentication. MEs isolated from bovine milk using sequential ultracentrifugation were authenticated as follows. As shown in FIG. 21A, nanoparticle tracking analysis (NTA) showed that MEs had a mean diameter of 106.6 ± 38.0 nm (mode: 88.1 nm) and a concentration of 9.35 x 1013particles / mL milk, which is within the size range expected for exosomes. As shown in FIG. 21B, transmission electron microscopy (TEM) showed that MEs had contours expected for exosomes and were finely dispersed in buffer. As shown in FIG. 20, DMEs w ere finely dispersed in phosphate-buffered saline, with less than about ten percent of vesicles attached to other vesicles across the three configurations, supporting a low aggregation profile under imaging conditions aligned with the authentication panels.

[0161] As shown in FIG. 21C, immunoblots showed that MEs expressed positive markers expected for exosomes (including CD63, HSP70, and Alix; immunoblots for CD9, CD81, and TsglOl not shown) and did not contain detectable amounts of markers for contamination with nanoparticles other than MEs, including apolipoprotein B-100, (3-integrin, histone H3, and butyrophilin. Non-detectability of these negative markers suggests that MEs were largely free of lipoproteins, small ectosomes, particles containing nuclear material, and fat globules, respectively. Casein micelles were also not detectable. As shown in FIG. 22, sequential purification by ultracentrifugation, size exclusion chromatography, sucrose density gradient centrifugation, and optional Ni2+-affinity chromatography enriched canonical exosome markers CD9, CD81, and TsglOl, when normalizing by vesicle count, consistent with improved homogeneity. As shown in FIG. 23, proteins frequently encountered in conventional milk exosome preparations, were reduced to non-detectable levels under these purification conditions, with appropriate positive controls for each matrix confirming assay performance. For example, a marker of nuclear material (histone H3) w as not detectable in input material and PMEs but was detectable in a2025-132-02positive control (proteins from murine brain). A marker of microvesicles / ectosomes (integrin beta 1) was not detectable in input material and PMEs but was detectable in positive control (bovine milk). A whey protein that forms aggregates with casein (betalactoglobulin) was detectable in input material but reduced to non-detectable levels when PMEs were purified using Ni2+ affinity resins. Traces of apoB-100 were detectable in input material but reduced to non-detectable levels in PMEs.

[0162] Studies of the marker proteins by immunoblot analyses were supplemented by micoRNA-sequencing analysis, and mass spectrometry7analysis of proteins and lipids in DME (heart, hippocampus, or pancreas homing DMEs prepared by UC, SEC. SDGC, and affinity purification) and input material (naive milk exosomes, purified by UC). MicoRNA-sequencing data is consistent with our hypothesis that additional purification steps improved the homogeneity7of preparations (Table 2). A comprehensive list of microRNAs is attached to this report (see below). The purification steps (UC, SEC, SDGC, and affinity7chromatography) employed in the preparation of PMEs resulted in an enrichment of known exosome marker proteins compared to input material purified by UC; Table 3). For lipids, 301 to 495 lipid signatures were detected in DMEs and input material.

[0163] These results demonstrate that the starting material for DME preparation meets the authentication criteria recommended by the International Society for Extracellular Vesicles (ISEV).Table 2. Unique microRNAs in PMEs and input material3PME Configuration (Target tissue) and Unique microRNAs (M)Control1: EE-Nebraska-HeartOOl 1882: EE-Nebraska-HippocampusOOl 1883: EE-Nebraska-PancreasOOl 2464 Input material 239Tor each preparation, one independent replicate was prepared and analyzed.Table 3. Exosome marker proteins in PMEs and input material3PME Configuration (Target tissue) and Marker proteins (w)bControl1: EE-Nebraska-HeartOOl 762: EE-Nebraska-HippocampusOOl 773: EE-Nebraska-PancreasOOl 764 Input material 69Tor each preparation, one independent replicate was prepared and analyzed.bOut of the 100 most abundant exosome marker proteins.2025-132-02Example 14: DNA content of bovine milk exosomes and surface association of trace DNA

[0164] This example describes the quantification of DNA associated with bovine milk exosomes (BMEs) and demonstrates that essentially all detectable DNA is adsorbed to the outer surface of BMEs rather than encapsulated within the vesicle lumen, supporting a low risk of uncontrolled DNA transfer by BMEs. BMEs prepared and purified as described herein were analyzed under three conditions: untreated BMEs, DNase-treated BMEs, and resuspend buffer only (negative control). DNase treatment degrades externally accessible, surface-bound DNA but cannot penetrate the vesicle membrane to reach any internally encapsulated DNA. As shown in FIG. 26A, untreated BMEs carried approximately 250-545 ng of DNA per IxlO10BMEs, but after DNase treatment, the DNA content dropped to levels that were not statistically significant from the buffer-only control, demonstrating that there is almost no DNA inside BMEs. As shown in FIG.26B, when carrier RNA was added to improve DNA recovery sensitivity. DNase-treated BMEs remained statistically indistinguishable from the buffer-only control, confirming that enhanced extraction efficiency does not reveal hidden internal DNA. These findings establish that the DNA originally detected in untreated BME preparations resides on the vesicle exterior rather than within the lumen, adsorbed to the outer surface of BMEs. The results indicate a low risk of uncontrolled DNA transfer by BMEs.

[0165] In an embodiment, the certificate of analysis of hippocampus homing DMEs loaded with CRISPR / Cas9 is shown in Table 4.Table 4. Certificate of AnalysisTest Unit Result Comment / Regulatory Standard PME count PMEs / mL 1014DMEs Dose: <1 mL / kg body weightin 1.0 mLEndotoxins EU / mL 0.08 Below FDA / EMA limit (<0.5 EU / mL) Microbial growth CFU / mL ND Goal: <10 CFU / mL (Gram+, Gram-, fungi) Homogeneity Fold 12.5 In naive Mes, 239 miRNAs, 812 proteins,SEC / SDGC / Ni2+vs and 301 lipids were identified.! In DMEs, UC 188 miRNAs. 1492 proteins, and 440 lipids were identified. Purification of DMEs by SEC, SDGC, and affinity chromatography caused an enrichment of exosome marker miRNAs and proteins.2025-132-02Diameter nm 53.4 Consistent with exosome size range (30- 150 nm)Dispersion % aggregate <10% MEs disbursed in PBS / trehalose in prior studiesDensity g / mL 1.08-1.19 Consistent with exosome density range Marker proteins Detect / ND See Slide 8 Positive: >3 of CD9, CD63, CD81, HSP70.Alix. TsglOlNegative: apoB-100, P-integrin, P- lactoglobulin. butyrophilin, histone H3 Peptide purity % >96.3% HPLC & mass spectrometry (vendor COA) H5N1 (avian flu) Ct (qPCR) >40 (ND) Positive control tested at Ct=28±0.03;H5N 1 inactivated by HPPND = Not Detectable | UC = Ultracentrifugation | HPP = High Pressure Processing | CFU = Colony Forming Units

[0166] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described in any way.

[0167] In one aspect, the present disclosure provides a small extracellular vesicle (sEV) comprising a tissue homing peptide attached to the sEV.

[0168] In some embodiments, the sEV is derived from mammalian milk, or comprises a size, morphology, and bioavailability equivalent to an sEV derived from mammalian milk.

[0169] In certain embodiments, the tissue homing peptide comprises a carbonyl-reactive peptide, and binds covalently to a carbonyl residue on the sEV surface. In specific embodiments, the carbonyl residue is on a CD81 protein on the sEV surface.

[0170] In embodiments, the tissue homing peptide is a brain homing peptide, a hippocampus homing peptide, a neuron homing peptide, a heart homing peptide, a pancreas homing peptide, a lung homing peptide, a liver homing peptide, or a cancer homing peptide. In some embodiments, the tissue homing peptide comprises a rabies virus glycoprotein (RVG)-derived peptide and / or Tetl.

[0171] In certain embodiments, the tissue homing peptide is a hippocampus homing peptide and comprises the amino acid sequence of CDAGRKQKC (SEQ ID NO: 1). In specific embodiments, the tissue homing peptide is a heart homing peptide and comprises the amino acid sequence of CRPPR (SEQ ID NO: 2). In embodiments, the tissue homing peptide is a pancreas homing peptide and comprises the amino acid sequence of LSALPRT (SEQ ID NO: 3). In some embodiments, the tissue homing peptide is a lung homing peptide and comprises2025-132-02the amino acid sequence of CTSTRKKQC (SEQ ID NO: 4). In certain embodiments, the tissue homing peptide is a liver homing peptide and comprises the amino acid sequence of RDEAKRF (SEQ ID NO: 5). In specific embodiments, the tissue homing peptide is a cancer homing peptide. In embodiments, the cancer homing peptide is a glioma homing peptide and comprises CooP or apoE.

[0172] In some embodiments, the tissue homing peptide comprises a tag. In certain embodiments, the tag is a histidine tag. In specific embodiments, the tissue homing peptide further comprises one or more spacers. In embodiments, the tissue homing peptide comprises the amino acid sequence of GSGHHHHHHGSG (SEQ ID NO: 6).

[0173] In some embodiments, the sEV comprises cargo. In certain embodiments, the cargo comprises a gene editing agent, a protein, a plasmid, or a small interfering RNA. In specific embodiments, the gene editing agent comprises a CRISPR-Cas9 enzyme and a guide RNA. In embodiments, the plasmid encodes SYNGAP1 or MAGEL2.

[0174] In some embodiments, the sEV has a size of about 30 to about 150 nm.

[0175] In certain embodiments, the sEV further comprises a detectable label. In specific embodiments, the detectable label comprises a fluorophore, a chemiluminescent dye, a pH-sensitive dye, or a combination thereof.

[0176] In embodiments, the sEV further comprises a CD47 peptide attached to the sEV.

[0177] In one aspect, the present disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of the sEV as described herein. In some embodiments, the sEV is lyophilized and the pharmaceutical composition comprises about 3% trehalose.

[0178] In one aspect, the present disclosure provides a method of delivering a therapeutic molecule to a target tissue or a target organ in a subject, the method comprising administering a therapeutically effective amount of a small extracellular vesicle (sEV) comprising a tissue homing peptide attached to the sEV and the therapeutic molecule.

[0179] In certain embodiments, the sEV is derived from mammalian milk, or comprises a size, morphology', and bioavailability equivalent to an sEV derived from mammalian milk. In specific embodiments, the tissue homing peptide comprises a carbonyl-reactive peptide, and binds covalently to a carbonyl residue on the sEV surface.

[0180] In embodiments, the tissue homing peptide is a brain homing peptide, a neuron homing peptide, a hippocampus homing peptide, a heart homing peptide, a pancreas homing2025-132-02peptide, a lung homing peptide, a liver homing peptide, or a cancer homing peptide. In some embodiments, the tissue homing peptide comprises a rabies virus glycoprotein (RVG)-derived peptide and / or Tetl.

[0181] In certain embodiments, the tissue homing peptide is a hippocampus homing peptide and comprises the amino acid sequence of CDAGRKQKC (SEQ ID NO: 1); the tissue homing peptide is a heart homing peptide and comprises the amino acid sequence of CRPPR (SEQ ID NO: 2); the tissue homing peptide is a pancreas homing peptide and comprises the amino acid sequence of LSALPRT (SEQ ID NO: 3); the tissue homing peptide is a lung homing peptide and comprises the amino acid sequence of CTSTRKKQC (SEQ ID NO: 4); the tissue homing peptide is a liver homing peptide and comprises the amino acid sequence of RDEAKRF (SEQ ID NO: 5); or the tissue homing peptide is a cancer homing peptide, wherein the cancer homing peptide is a glioma homing peptide and comprises CooP or apoE.

[0182] In specific embodiments, the tissue homing peptide comprises a tag and / or one or more spacers. In embodiments, the tissue homing peptide comprises the amino acid sequence of GSGHHHHHHGSG (SEQ ID NO: 6).

[0183] In some embodiments, the therapeutic molecule comprises a gene editing agent, a protein, a plasmid, or a small interfering RNA. In certain embodiments, the gene editing agent comprises a CRISPR-Cas9 enzy me and a guide RNA. In specific embodiments, the plasmid encodes SYNGAP1 orMAGEL2.

[0184] In embodiments, the sEV further comprises a detectable label. In some embodiments, the sEV further comprises a CD47 peptide attached to the sEV.

[0185] In one aspect, the present disclosure provides a method of modifying a small extracellular vesicle (sEV), the method comprising attaching a carbonyl-reactive peptide to a carbonyl residue on the sEV surface.

[0186] In certain embodiments, the carbonyl-reactive peptide is a tissue homing peptide. In specific embodiments, the tissue homing peptide is a brain homing peptide, a hippocampus homing peptide, a neuron homing peptide, a heart homing peptide, a pancreas homing peptide, a lung homing peptide, a liver homing peptide, or a cancer homing peptide. In embodiments, the tissue homing peptide comprises a rabies virus glycoprotein (RVG)-derived peptide and / or Tetl.

[0187] In some embodiments, the tissue homing peptide is a hippocampus homing peptide and comprises the amino acid sequence of CDAGRKQKC (SEQ ID NO: 1); the tissue homing peptide is a heart homing peptide and comprises the amino acid sequence of CRPPR (SEQ ID2025-132-02NO: 2); the tissue homing peptide is a pancreas homing peptide and comprises the amino acid sequence of LSALPRT (SEQ ID NO: 3); the tissue homing peptide is a lung homing peptide and comprises the amino acid sequence of CTSTRKKQC (SEQ ID NO: 4); the tissue homing peptide is a liver homing peptide and comprises the amino acid sequence of RDEAKRF (SEQ ID NO: 5); or the tissue homing peptide is a cancer homing peptide, wherein the cancer homing peptide is a glioma homing peptide and comprises CooP or apoE.

[0188] In certain embodiments, the tissue homing peptide comprises a tag and / or one or more spacers. In specific embodiments, the tissue homing peptide comprises the amino acid sequence of GSGHHHHHHGSG (SEQ ID NO: 6).

[0189] In embodiments, the method further comprises loading cargo onto the sEV. In some embodiments, the cargo comprises a gene editing agent, a protein, a plasmid, or a small interfering RNA. In certain embodiments, the gene editing agent comprises a CRISPR-Cas9 enzyme and a guide RNA. In specific embodiments, the plasmid encodes SYNGAP1 or MAGEL2.

[0190] In embodiments, the method further comprises lyophilizing the sEV with about 3% trehalose. In some embodiments, the method further comprises capturing the sEV on a Ni2+-charged affinity resin, and purifying the sEV. In certain embodiments, the method further comprises sterilizing the sEV by filtration through a membrane filter followed by high-pressure processing.

[0191] In one aspect, the present disclosure provides a method of treating a disease in a subject, the method comprising administering a therapeutically effective amount of a small extracellular vesicle (sEV) comprising a tissue homing peptide attached to the sEV and a therapeutic molecule, wherein the sEV delivers the therapeutic molecule to a target tissue or organ affected by the disease. In specific embodiments, the disease is glioblastoma multiforme, SYNGAP1 haploinsufficiency, a MAGEL2-associated disease, heart disease, or a rare disease.SEQUENCE TABLE SEQ ID Sequence Description SequenceNO:1 Amino acid sequence of a CDAGRKQKChippocampus homing peptide2 Amino acid sequence of a CRPPRheart homing peptide3 Amino acid sequence of a LSALPRTpancreas homing peptide2025-132-024 Amino acid sequence of a CTSTRKKQClung homing peptide5 Amino acid sequence of a RDEAKRFliver homing peptide6 Amino acid sequence of a GSGHHHHHHGSGHis6 tag with spacers7 Amino acid sequence of Tetl HLNILSTLWKYR8 Amino acid sequence of YTIWMPENPRPGTPCDIFTNSRGKRASNG Rabies Virus Glycoprotein(RVG)9 Amino acid sequence of CooP CGLSGLGVA

[0192] Other objects, features, and advantages of the disclosure will become apparent from the foregoing figures, detailed description, and examples. It should be understood, however, that the figures, detailed description, and examples, while indicating specific embodiments of the disclosure, are given by way of illustration only and are not meant to be limiting. Additionally, it is contemplated that changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from the detailed description. In further embodiments, features from specific embodiments may be combined w ith features from other embodiments. For example, features from one embodiment may be combined with features from any of the other embodiments. In further embodiments, additional features may be added to the specific embodiments described herein.

Claims

2025-132-02CLAIMSWhat is claimed is:

1. A small extracellular vesicle (sEV) comprising a tissue homing peptide attached to the sEV.

2. The sEV of claim 1, wherein the sEV is derived from mammalian milk, or comprises a size, morphology, and bioavailability equivalent to an sEV derived from mammalian milk.

3. The sEV of claim 1, wherein the tissue homing peptide comprises a carbonyl-reactive peptide, and binds covalently to a carbonyl residue on the sEV surface.

4. The sEV of any one of claims 1-3, wherein the tissue homing peptide is a brain homing peptide, a hippocampus homing peptide, a neuron homing peptide, a heart homing peptide, a pancreas homing peptide, a lung homing peptide, a liver homing peptide, or a cancer homing peptide.

5. The sEV of any one of claims 1-4, wherein the tissue homing peptide comprises a rabies virus glycoprotein (RVG)-derived peptide and / or Tetl.

6. The sEV of claim 4, wherein the tissue homing peptide is a hippocampus homing peptide and comprises the amino acid sequence of CDAGRKQKC (SEQ ID NO: 1); wherein the tissue homing peptide is a heart homing peptide and comprises the amino acid sequence of CRPPR (SEQ ID NO: 2); wherein the tissue homing peptide is a pancreas homing peptide and comprises the amino acid sequence of LSALPRT (SEQ ID NO: 3); wherein the tissue homing peptide is a lung homing peptide and comprises the amino acid sequence of CTSTRKKQC (SEQ ID NO: 4); wherein the tissue homing peptide is a liver homing peptide and comprises the amino acid sequence of RDEAKRF (SEQ ID NO: 5); or wherein the tissue homing peptide is a cancer homing peptide comprising a glioma homing peptide and comprises CooP or apoE.

7. The sEV of any one of claims 1-6, wherein the tissue homing peptide comprises a tag and / or one or more spacers.

8. The sEV of claim 7, wherein the tissue homing peptide comprises the amino acid sequence of GSGHHHHHHGSG (SEQ ID NO: 6).

9. The sEV of any one of claims 1-8, wherein the sEV comprises cargo.

10. The sEV of claim 9, wherein the cargo comprises a gene editing agent, a protein, a plasmid, or a small interfering RNA.2025-132-0211. The sEV of claim 10, wherein the gene editing agent comprises a CRISPR-Cas9 enzyme and a guide RNA.

12. The sEV of claim 10, wherein the plasmid encodes SYNGAP1 or MAGEL2.

13. A pharmaceutical composition comprising a therapeutically effective amount of the sEV of any one of claims 1 to 12.

14. The pharmaceutical composition of claim 13, wherein the sEV is lyophilized and the pharmaceutical composition comprises about 3% trehalose.

15. A method of delivering a therapeutic molecule to a target tissue or a target organ in a subject, the method comprising administering a therapeutically effective amount of the sEV of any one of claims 1 to 12, wherein the sEV comprises the therapeutic molecule.

16. A method of modifying a small extracellular vesicle (sEV) to produce the sEV of any one of claims 1 to 12, the method comprising attaching a carbonyl-reactive peptide to a carbonyl residue on the sEV surface.

17. The method of claim 16, further comprising loading cargo onto the sEV.

18. The method of claim 16 or 17, further comprising capturing the sEV on aNi2+-charged affinity resin and purifying the sEV.

19. A method of treating a disease in a subject, the method comprising administering a therapeutically effective amount of the sEV of any one of claims 1 to 12, wherein the sEV comprises a therapeutic molecule and delivers the therapeutic molecule to a target tissue or organ affected by the disease.

20. The method of claim 19, wherein the disease is glioblastoma multiforme, SYNGAP1 haploinsufficiency, a MAGEL2-associated disease, heart disease, or a rare disease.